Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
or

Adaptive Biotechnologies Corp (ADPT)

Adaptive Biotechnologies Corp (ADPT)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
7.52 +0.09 (+1.21%) 04/01/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 7.52 unch (unch) 16:02 ET
Quote Overview for Tue, Apr 1st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
7.13
Day High
7.63
Open 7.35
Previous Close 7.43 7.43
Volume 2,403,200 2,403,200
Avg Vol 2,280,090 2,280,090
Stochastic %K 34.94% 34.94%
Weighted Alpha +152.70 +152.70
5-Day Change -0.90 (-10.69%) -0.90 (-10.69%)
52-Week Range 2.28 - 9.01 2.28 - 9.01
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,103,964
  • Shares Outstanding, K 148,582
  • Annual Sales, $ 178,960 K
  • Annual Income, $ -159,490 K
  • EBIT $ -154 M
  • EBITDA $ -143 M
  • 60-Month Beta 1.53
  • Price/Sales 6.37
  • Price/Cash Flow N/A
  • Price/Book 5.59

Options Overview Details

View History
  • Implied Volatility 95.93% ( +11.48%)
  • Historical Volatility 65.27%
  • IV Percentile 27%
  • IV Rank 13.59%
  • IV High 573.92% on 04/19/24
  • IV Low 20.76% on 10/03/24
  • Put/Call Vol Ratio 0.06
  • Today's Volume 34
  • Volume Avg (30-Day) 69
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 1,493
  • Open Int (30-Day) 1,418

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.28
  • Number of Estimates 4
  • High Estimate -0.26
  • Low Estimate -0.31
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +15.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.26 +20.22%
on 03/11/25
Period Open: 8.26
9.01 -16.54%
on 03/24/25
-0.74 (-8.96%)
since 02/28/25
3-Month
5.96 +26.17%
on 01/02/25
Period Open: 5.99
9.01 -16.54%
on 03/24/25
+1.53 (+25.44%)
since 12/31/24
52-Week
2.28 +229.82%
on 04/19/24
Period Open: 3.11
9.01 -16.54%
on 03/24/25
+4.41 (+141.80%)
since 04/01/24

Most Recent Stories

More News
Is Bio-Techne Corporation Stock Underperforming the S&P 500?

Despite Bio-Techne Corporation’s underperformance relative to the S&P 500 over the past year, analysts maintain a bullish outlook on the stock’s prospects.

TECH : 57.35 (-2.18%)
$SPX : 5,633.07 (+0.38%)
ADPT : 7.52 (+1.21%)
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

ADPT : 7.52 (+1.21%)
Adaptive Biotechnologies: Q4 Earnings Snapshot

Adaptive Biotechnologies: Q4 Earnings Snapshot

ADPT : 7.52 (+1.21%)
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

ADPT : 7.52 (+1.21%)
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

ADPT : 7.52 (+1.21%)
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

ADPT : 7.52 (+1.21%)
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

/CNW/ -- As 2025 begins, the American Association for Cancer Research (AACR) recently published forecasts from experts showcasing transformative advances in...

ONCY : 0.5270 (-4.18%)
ELEV : 0.2475 (-4.48%)
ORIC : 5.53 (-0.90%)
ADPT : 7.52 (+1.21%)
NEO : 9.35 (-1.48%)
ONC.TO : 0.77 (-2.53%)
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

ADPT : 7.52 (+1.21%)
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

ADPT : 7.52 (+1.21%)
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ADPT : 7.52 (+1.21%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage....

See More

Key Turning Points

3rd Resistance Point 8.22
2nd Resistance Point 7.93
1st Resistance Point 7.72
Last Price 7.52
1st Support Level 7.22
2nd Support Level 6.93
3rd Support Level 6.72

See More

52-Week High 9.01
Last Price 7.52
Fibonacci 61.8% 6.44
Fibonacci 50% 5.64
Fibonacci 38.2% 4.85
52-Week Low 2.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies